Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Nov-Dec;15(6):102322.
doi: 10.1016/j.dsx.2021.102322. Epub 2021 Oct 27.

COVID-19 associated mucormycosis: A Descriptive Multisite Study from India

Ritesh Gupta  1 , Jothydev Kesavadev  2 , Gopika Krishnan  2 , Sanjay Agarwal  3 , Banshi Saboo  4 , Meet Shah  5 , Atul Mittal  6 , Suhail Durani  6 , Atul Luthra  6 , Anuj Singhal  7 , Muhammed Rasheed  8 , G V S Rao  9 , Vidit Tripathi  10 , Alka Jha  10 , Amerta Ghosh  11 , V Mohan  12 , Awadhesh K Singh  13 , Sanjeev Phatak  14 , John Panicker  15 , Sanjay Kumar Bhadada  16 , Shashank Joshi  17 , Rimesh Pal  16 , Ambrish Mithal  18 , Naval Vikram  19 , Anoop Misra  11
Affiliations
Observational Study

COVID-19 associated mucormycosis: A Descriptive Multisite Study from India

Ritesh Gupta et al. Diabetes Metab Syndr. 2021 Nov-Dec.

Abstract

Background and aims: Mucormycosis is an invasive fungal infection and carries a significant morbidity and mortality. A number of cases of mucormycosis have been reported in association with COVID-19. In this study, a consortium of clinicians from various parts of India studied clinical profile of COVID-19 associated mucormycosis (CAM) and this analysis is presented here.

Methods: Investigators from multiple sites in India were involved in this study. Clinical details included the treatment and severity of COVID-19, associated morbidities, as well as the diagnosis, treatment and prognosis of mucormycosis. These data were collected using google spreadsheet at one centre. Descriptive analysis was done.

Results: There were 115 patients with CAM. Importantly, all patients had received corticosteroids. Diabetes was present in 85.2% of patients and 13.9% of patients had newly detected diabetes. The most common site of involvement was rhino-orbital. Mortality occurred in 25 (21.7%) patients. On logistic regression analysis, CT scan-based score for severity of lung involvement was associated with mortality.

Conclusion: Universal administration of corticosteroids in our patients is notable. A large majority of patients had diabetes, while mortality was seen in ∼1/5th of patients, lower as compared to recently published data.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest There is no conflict of interest of any author regarding the manuscript “COVID-19 Associated Mucormycosis: A Descriptive Multisite Study from India”.

Figures

Fig. 1
Fig. 1
Distribution of patients according to the site of involvement by mucormycosis (n,115).
See this image and copyright information in PMC

References

    1. Palanisamy N., et al. Clinical profile of bloodstream infections in COVID-19 patients: a retrospective cohort study. BMC Infect Dis. 2021;21(1):933. - PMC - PubMed
    1. Zia M., Goli M. Predisposing factors of important invasive fungal coinfections in COVID-19 patients: a review article. J Int Med Res. 2021;49(9) 3000605211043413-3000605211043413. - PMC - PubMed
    1. Unnikrishnan R., Misra A. Infections and diabetes: risks and mitigation with reference to India. Diabet Metabol Syndr. 2020 Nov-Dec;14(6):1889–1894. doi: 10.1016/j.dsx.2020.09.022. Epub 2020 Sep 22. PMID: 33002780; PMCID: PMC7505871. - DOI - PMC - PubMed
    1. Garg D., et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021;186(2):289–298. - PMC - PubMed
    1. Jose A., et al. Current understanding in the pathophysiology of SARS-CoV-2-associated rhino-orbito-cerebral mucormycosis: a comprehensive review. J Maxillofacial Oral Surg. 2021;20(3):1–8. - PMC - PubMed

Publication types

Substances